EGFR and dermatological toxicity: A retrospective exploration of several trials done with panitumumab, another anti-EGFR monoclonal antibody, confirmed an association between clinically graded skin toxicity and patient-reported outcome, quality of life, longer progression-free survival and overall survival [26].